-
公开(公告)号：US10774321B2
公开(公告)日：2020-09-15
申请号：US15310908
申请日：2015-05-20
IPC分类号： C12N9/96 , A61K47/02 , A61K47/26 , A61K47/10 , C12N9/64 , A61K47/16 , A61K38/46 , A61K38/48 , C12N15/52
摘要： A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.
-
公开(公告)号：US20200046877A1
公开(公告)日：2020-02-13
申请号：US16659830
申请日：2019-10-22
发明人： Yukako KAGEYAMA , Kentaro Fujinaga , Ayuko Yamaguchi , Yusuke Aklyama , Akitoshi Oono , Susumu Honda , Makoto Satake , Hiroaki Kaneko , Takayuki Imamura , Ryoichi Kawamura , Masaki Hirashima
摘要： A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.
-
公开(公告)号：US11357847B2
公开(公告)日：2022-06-14
申请号：US16641420
申请日：2018-08-29
IPC分类号： A61K39/245 , A61P31/22 , C07K14/005
摘要： The modified HSV gD protein of the present invention is a modified protein of a herpes simplex virus (HSV) envelope glycoprotein D (gD), wherein the modified HSV gD protein is derived from a wild-type HSV gD by modification of at least one of B cell epitopes having low or no neutralizing antibody-inducing activity compared to a B cell epitope present in a receptor-binding domain (RBD) (decotopes) in the ectodomain of the wild-type HSV gD, so that the modified epitope does not function as an epitope.
-
公开(公告)号：US10604562B2
公开(公告)日：2020-03-31
申请号：US15114600
申请日：2015-01-23
发明人： Akihiko Hosoi , Masaharu Torikai , Tomoyo Takeo , Masayo Ueno , Hirofumi Higuchi , Kenji Soejima , Toshihiro Nakashima , Yukio Ando , Hirofumi Jono , Yu Su
IPC分类号： C07K16/18 , A61K39/395 , G01N33/68 , A61K39/00 , C07K14/00
摘要： A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.
-
公开(公告)号：US20200095276A1
公开(公告)日：2020-03-26
申请号：US16471830
申请日：2017-12-20
发明人： Kentaro EBISU , Takashi KAI , Nozomi MATSUO
摘要： A chromatographic method for collecting blood coagulation factor VII (Factor VII) and/or activated blood coagulation factor VII (activated Factor VII) from plasma-derived fractions with high yield is provided. In accordance with the method of the present invention, Factor VII and/or activated Factor VII of interest can be collected with a recovery rate of as high as 90% or more by letting Factor VII and/or activated Factor VII which fails to be adsorbed to a first anion exchange resin and remains in a non-adsorption fraction be adsorbed in a second anion exchange resin.
-
公开(公告)号：US10570199B2
公开(公告)日：2020-02-25
申请号：US14442004
申请日：2013-11-18
IPC分类号： C07K16/24 , A61P37/06 , G01N33/68 , C12N15/10 , C12N15/62 , G01N33/538 , G01N33/543
摘要： The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.
-
公开(公告)号：US20220296697A1
公开(公告)日：2022-09-22
申请号：US17634488
申请日：2020-06-23
发明人： Takeshi ARAKAWA , Yukihiro TAMAKI , Kenichi YAMAZAKI , Jinya YAMADA , Nozomi TAIRA , Hirotaka UEFUJI , Ikuko YONAMINE , Tetsuya HARAKUNI , Rui YAMAGUCHI
IPC分类号： A61K39/12 , C07K14/005 , C07K14/315 , C07K19/00 , C12N15/62 , C12P21/02
摘要： Provided is PCV2 VLP that can be used as a vaccine for use in the field of animal husbandry and that has high molecular stability against physicochemical load. A fusion protein according to the present invention includes a capsid protein of porcine circovirus type 2 and an immunoglobulin-binding domain.
-
公开(公告)号：US11433160B2
公开(公告)日：2022-09-06
申请号：US16659830
申请日：2019-10-22
发明人： Yukako Kageyama , Kentaro Fujinaga , Ayuko Yamaguchi , Yusuke Akiyama , Akitoshi Oono , Susumu Honda , Makoto Satake , Hiroaki Kaneko , Takayuki Imamura , Ryoichi Kawamura , Masaki Hirashima
摘要： A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.
-
公开(公告)号：US20220275347A1
公开(公告)日：2022-09-01
申请号：US17632907
申请日：2020-08-07
发明人： Toshio MURAKAMI , Go OKITA , Yui KAMIZURU
IPC分类号： C12N7/00 , A61K35/768 , A61P35/00
摘要： Provided is an oncolytic virus having both improved safety and productivity. Provided are: a conditionally replicating vaccinia virus which lacks the functions of a vaccinia virus growth factor (VGF), an extracellular signal-regulated kinase (ERK) activation protein, and a ribonucleotide reductase (RNR), is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety; and a conditionally replicating vaccinia virus which lacks the functions of a VGF, an ERK activation protein, and an RNR, is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety and productivity, and in which a gene encoding an extracellular enveloped virus (EEV)-related protein is substituted with a gene corresponding to another vaccinia virus strain having a high EEV-producing ability.
-
公开(公告)号：US20220265896A1
公开(公告)日：2022-08-25
申请号：US17630301
申请日：2020-07-31
发明人： Hideki SAGA , Minako INUI , Noriko OGURA
IPC分类号： A61L27/22 , A61K38/36 , A61L27/36 , A61L27/56 , A61L27/58 , A61L31/00 , A61L31/04 , A61L31/14
摘要： A problem to be solved by the present invention is to provide a fibrosis inhibitor that solves the problem of inhibiting fibrosis of an organ or tissue surface, and especially of inhibiting fibrosis of an epicardial surface. Furthermore, by inhibiting fibrosis, the present invention prevents or reduces subsequent development of adhesions to avoid organ or tissue damage during re-operation. Provided is a fibrosis inhibitor for inhibiting fibrosis of a tissue by fixing a biocompatible polymer to a tissue where it is desirable to inhibit fibrosis.
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.023 秒)